Unless I'm mistaken, Cel-Sci's strategy is to first have the full results of the P3 trial published in a scholarly, peer-reviewed journal, and then to seek a pre-BLA meeting with the FDA to discuss the path forward for approval of MK. To that end, here is a quote from a scientist employed by a different biotech company, that I found to be rather insightful regarding the process of earning publication in a prestigious journal (this company just concluded a P2b trial in which they met their primary and secondary endpoints):
"However, due to the strict disclosure policies of the prestigious clinical journals, which only permit limited data to be released at closed scientific meetings, the Company is unable at this time to release the entire data set with information that it believes would provide greater clarity around the results. Any further disclosures of the clinical data may disqualify the trial from publication, a situation the Company wishes to avoid. Although publication may be several months away as the peer review process typically involves several iterations of questions and clarifications, publication in a peer-reviewed journal will lend significant credence to the work and represent significant progress in the field of..."
Geert has repeatedly stated that, in order to ultimately succeed, things have to be done the right way the first time. I believe that is why he has been silent on Twitter, and that is why the company has been in information lockdown since July. The company's priority is to get the results of the P3 trial published, which will help them when they meet with the FDA. I am long here.
